{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:23:49Z","timestamp":1772166229992,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,6,28]],"date-time":"2023-06-28T00:00:00Z","timestamp":1687910400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,28]],"date-time":"2023-06-28T00:00:00Z","timestamp":1687910400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Suzhou Key Technology (Research) Project for the Prevention and Control of Major Diseases and Infectious Diseases","award":["GWZX201902"],"award-info":[{"award-number":["GWZX201902"]}]},{"name":"Suzhou Key Technology (Research) Project for the Prevention and Control of Major Diseases and Infectious Diseases","award":["GWZX202002"],"award-info":[{"award-number":["GWZX202002"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This retrospective study aimed to characterize the distribution of HIV-1 genotypes and the prevalence of drug resistance mutations in people with antiretroviral treatment (ART) failure in Suzhou City, China.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Pol gene of HIV-1 viruses in blood samples of EDTA anticoagulants from 398 patients with failed antiviral treatment was successfully amplified by using an in-house assay. Drug resistance mutations were analyzed by using the Stanford HIV Drug Resistance Database system (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/hivdb.stanford.edu\/hivdb\/by-mutations\/\">https:\/\/hivdb.stanford.edu\/hivdb\/by-mutations\/<\/jats:ext-link>\n                      ). HIV-1 genotypes were determined by the REGA HIV subtyping tool (version 3.46,\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.genomedetective.com\/app\/typingtool\/hiv\">https:\/\/www.genomedetective.com\/app\/typingtool\/hiv<\/jats:ext-link>\n                      ). Near full-length genomes (NFLG) of HIV-1 viruses were obtained by next generation sequencing method.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Sequences analysis of the\n                      <jats:italic>pol<\/jats:italic>\n                      gene revealed that CRF 01_AE (57.29%, 228\/398) was the dominant subtype circulating in Suzhou City, followed by CRF 07_BC (17.34%, 69\/398), subtype B (7.54%, 30\/398), CRF 08_BC (6.53%, 26\/398), CRF 67_01B (3.02%, 12\/398) and CRF55_01B (2.51%, 10\/398). The overall prevalence of drug-resistant mutations in cases with ART failure was 64.57% (257\/398), including 45.48% (181\/398) for nucleotide reverse transcriptase inhibitors (NRTIs) mutations, 63.32% (252\/398) for non-nucleoside reverse transcriptase inhibitors (NNRTIs) mutations, and 3.02% (12\/398) for protease inhibitors (PIs) mutations. Ten near full-length genomes (NFLG) of HIV-1 viruses were identified, including six recombinants of CRF 01_AE and subtype B, two recombinants of CRF 01_AE, subtype B and subtype C sequences, one recombinant of CRF 01_AE and subtype C and one recombinant of CRF 01_AE, subtype A1 and subtype C.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The high prevalence of drug-resistant HIV-1 viruses was a serious challenge for HIV prevention and treatment of people with HIV infection. Treatment regimens for ART failure patients should be adjusted over time based on the outcome of drug resistance tests. NFLG sequencing facilitates the identification of new recombinants of HIV-1.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12981-023-00540-0","type":"journal-article","created":{"date-parts":[[2023,6,28]],"date-time":"2023-06-28T04:02:24Z","timestamp":1687924944000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Genetic characterization of HIV-1 viruses among cases with antiretroviral therapy failure in Suzhou City, China"],"prefix":"10.1186","volume":"20","author":[{"given":"Zefeng","family":"Dong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhihui","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Runfang","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Di","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuerong","family":"Ya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,6,28]]},"reference":[{"key":"540_CR1","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/imr.12823","volume":"292","author":"C Fenwick","year":"2019","unstructured":"Fenwick C, Joo V, Jacquier P, Noto A, Banga R, Perreau M, Pantaleo G. T-cell exhaustion in HIV infection. Immunol Rev. 2019;292:149\u201363. https:\/\/doi.org\/10.1111\/imr.12823.","journal-title":"Immunol Rev"},{"key":"540_CR2","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1053\/j.semdp.2017.05.001","volume":"34","author":"C Del Rio","year":"2017","unstructured":"Del Rio C. The global HIV epidemic: what the pathologist needs to know. Semin Diagn Pathol. 2017;34:314\u20137. https:\/\/doi.org\/10.1053\/j.semdp.2017.05.001.","journal-title":"Semin Diagn Pathol"},{"key":"540_CR3","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1097\/QAI.0b013e3181bf1a25","volume":"53","author":"C van Tienen","year":"2010","unstructured":"van Tienen C, van der Loeff MS, Zaman SMA, Vincent T, Sarge-Njie R, Peterson I, et al. Two distinct epidemics: the rise of HIV-1 and decline of HIV-2 infection between 1990 and 2007 in rural Guinea-Bissau. J Acquir Immune Defic Syndr. 2010;53:640\u20137. https:\/\/doi.org\/10.1097\/QAI.0b013e3181bf1a25.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"540_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-4614-9610-6_34-1","volume-title":"Encyclopedia of AIDS","author":"C van Tienen","year":"2016","unstructured":"van Tienen C, van der Loeff MS. Epidemiology of HIV-2 infection in West Africa. In: Hope TJ, Stevenson M, Richman D, editors. Encyclopedia of AIDS. New York: Springer; 2016. p. 1\u201311. https:\/\/doi.org\/10.1007\/978-1-4614-9610-6_34-1."},{"key":"540_CR5","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1097\/COH.0000000000000534","volume":"14","author":"N Bbosa","year":"2019","unstructured":"Bbosa N, Kaleebu P, Ssemwanga D. HIV subtype diversity worldwide. Curr Opin HIV AIDS. 2019;14:153\u201360. https:\/\/doi.org\/10.1097\/COH.0000000000000534.","journal-title":"Curr Opin HIV AIDS"},{"key":"540_CR6","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S1473-3099(18)30647-9","volume":"19","author":"J Hemelaar","year":"2019","unstructured":"Hemelaar J, Elangovan R, Yun J, Dickson-Tetteh L, Fleminger I, Kirtley S, et al. Global and regional molecular epidemiology of HIV-1, 1990\u20132015: a systematic review, global survey, and trend analysis. Lancet Infect Dis. 2019;19:143\u201355. https:\/\/doi.org\/10.1016\/S1473-3099(18)30647-9.","journal-title":"Lancet Infect Dis"},{"key":"540_CR7","doi-asserted-by":"publisher","first-page":"a006841","DOI":"10.1101\/cshperspect.a006841","volume":"1","author":"PM Sharp","year":"2011","unstructured":"Sharp PM, Hahn BH. Origins of HIV and the AIDS pandemic. Cold Spring Harb Perspect Med. 2011;1:a006841. https:\/\/doi.org\/10.1101\/cshperspect.a006841.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"540_CR8","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1128\/JVI.02302-15","volume":"90","author":"M Tongo","year":"2015","unstructured":"Tongo M, Dorfman JR, Martin DP. High degree of HIV-1 Group M (HIV-1M) genetic diversity within circulating recombinant forms: insight into the early events of HIV-1M evolution. J Virol. 2015;90:2221\u20139. https:\/\/doi.org\/10.1128\/JVI.02302-15.","journal-title":"J Virol"},{"key":"540_CR9","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1016\/S1473-3099(16)30212-2","volume":"17","author":"T Peter","year":"2017","unstructured":"Peter T, Ellenberger D, Kim AA, Boeras D, Messele T, Roberts T, et al. Early antiretroviral therapy initiation: access and equity of viral load testing for HIV treatment monitoring. Lancet Infect Dis. 2017;17:e26\u20139. https:\/\/doi.org\/10.1016\/S1473-3099(16)30212-2.","journal-title":"Lancet Infect Dis"},{"key":"540_CR10","doi-asserted-by":"publisher","first-page":"e1002729","DOI":"10.1371\/journal.pmed.1002729","volume":"16","author":"J Jones","year":"2019","unstructured":"Jones J, Sullivan PS, Curran JW. Progress in the HIV epidemic: identifying goals and measuring success. PLoS Med. 2019;16:e1002729. https:\/\/doi.org\/10.1371\/journal.pmed.1002729.","journal-title":"PLoS Med"},{"key":"540_CR11","doi-asserted-by":"publisher","first-page":"e588","DOI":"10.1016\/S2352-3018(18)30173-5","volume":"5","author":"RL Hamers","year":"2018","unstructured":"Hamers RL, Rinke de Wit TF, Holmes CB. HIV drug resistance in low-income and middle-income countries. Lancet HIV. 2018;5:e588\u201396. https:\/\/doi.org\/10.1016\/S2352-3018(18)30173-5.","journal-title":"Lancet HIV"},{"key":"540_CR12","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/s12879-018-3130-9","volume":"18","author":"Q Xuan","year":"2018","unstructured":"Xuan Q, Liang S, Qin W, Yang S, Zhang A-M, Zhao T, et al. High prevalence of HIV-1 transmitted drug resistance among therapy-na\u00efve Burmese entering travelers at Dehong ports in Yunnan, China. BMC Infect Dis. 2018;18:211. https:\/\/doi.org\/10.1186\/s12879-018-3130-9.","journal-title":"BMC Infect Dis"},{"key":"540_CR13","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s12981-017-0133-3","volume":"14","author":"X Lu","year":"2017","unstructured":"Lu X, Zhao H, Zhang Y, Wang W, Zhao C, Li Y, et al. HIV-1 drug-resistant mutations and related risk factors among HIV-1-positive individuals experiencing treatment failure in Hebei Province, China. AIDS Res Ther. 2017;14:4. https:\/\/doi.org\/10.1186\/s12981-017-0133-3.","journal-title":"AIDS Res Ther"},{"key":"540_CR14","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.3389\/fmicb.2015.01258","volume":"6","author":"H Ode","year":"2015","unstructured":"Ode H, Matsuda M, Matsuoka K, Hachiya A, Hattori J, Kito Y, et al. Quasispecies analyses of the HIV-1 near-full-length genome with illumina MiSeq. Front Microbiol. 2015;6:1258. https:\/\/doi.org\/10.3389\/fmicb.2015.01258.","journal-title":"Front Microbiol"},{"key":"540_CR15","doi-asserted-by":"publisher","first-page":"20035","DOI":"10.7448\/IAS.18.1.20035","volume":"18","author":"S Grossmann","year":"2015","unstructured":"Grossmann S, Nowak P, Neogi U. Subtype-independent near full-length HIV-1 genome sequencing and assembly to be used in large molecular epidemiological studies and clinical management. J Int AIDS Soc. 2015;18:20035. https:\/\/doi.org\/10.7448\/IAS.18.1.20035.","journal-title":"J Int AIDS Soc"},{"key":"540_CR16","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.coph.2019.03.003","volume":"48","author":"A Bandera","year":"2019","unstructured":"Bandera A, Gori A, Clerici M, Sironi M. Phylogenies in ART: HIV reservoirs, HIV latency and drug resistance. Curr Opin Pharmacol. 2019;48:24\u201332. https:\/\/doi.org\/10.1016\/j.coph.2019.03.003.","journal-title":"Curr Opin Pharmacol"},{"key":"540_CR17","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.idc.2019.05.004","volume":"33","author":"SM McCluskey","year":"2019","unstructured":"McCluskey SM, Siedner MJ, Marconi VC. Management of virologic failure and HIV drug resistance. Infect Dis Clin N Am. 2019;33:707\u201342. https:\/\/doi.org\/10.1016\/j.idc.2019.05.004.","journal-title":"Infect Dis Clin N Am"},{"key":"540_CR18","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.ijid.2020.02.020","volume":"95","author":"EMT Salvana","year":"2020","unstructured":"Salvana EMT, Samonte GMJ, Telan E, Leyritana K, Tactacan-Abrenica RJ, Ching PR, et al. High rates of tenofovir failure in a CRF01_AE-predominant HIV epidemic in the Philippines. Int J Infect Dis. 2020;95:125\u201332. https:\/\/doi.org\/10.1016\/j.ijid.2020.02.020.","journal-title":"Int J Infect Dis"},{"key":"540_CR19","doi-asserted-by":"publisher","first-page":"e1002537","DOI":"10.1371\/journal.pmed.1002537","volume":"15","author":"JD Stekler","year":"2018","unstructured":"Stekler JD, Milne R, Payant R, Beck I, Herbeck J, Maust B, et al. Transmission of HIV-1 drug resistance mutations within partner-pairs: a cross-sectional study of a primary HIV infection cohort. PLoS Med. 2018;15:e1002537. https:\/\/doi.org\/10.1371\/journal.pmed.1002537.","journal-title":"PLoS Med"},{"key":"540_CR20","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1097\/QAI.0000000000002689","volume":"87","author":"C Bossard","year":"2021","unstructured":"Bossard C, Schramm B, Wanjala S, Jain L, Mucinya G, Opollo V, et al. High prevalence of NRTI and NNRTI drug resistance among ART-experienced, hospitalized inpatients. J Acquir Immune Defic Syndr. 2021;87:883\u20138. https:\/\/doi.org\/10.1097\/QAI.0000000000002689.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"540_CR21","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12985-020-1281-y","volume":"17","author":"D Zhang","year":"2020","unstructured":"Zhang D, Wu J, Zhang Y, Shen Y, Dai S, Wang X, et al. Genetic characterization of HIV-1 epidemic in Anhui Province, China. Virol J. 2020;17:17. https:\/\/doi.org\/10.1186\/s12985-020-1281-y.","journal-title":"Virol J"},{"key":"540_CR22","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s12985-020-01311-3","volume":"17","author":"X Zou","year":"2020","unstructured":"Zou X, He J, Zheng J, Malmgren R, Li W, Wei X, et al. Prevalence of acquired drug resistance mutations in antiretroviral-experiencing subjects from 2012 to 2017 in Hunan Province of central South China. Virol J. 2020;17:38. https:\/\/doi.org\/10.1186\/s12985-020-01311-3.","journal-title":"Virol J"},{"key":"540_CR23","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1186\/s12879-019-3927-1","volume":"19","author":"Z Wang","year":"2019","unstructured":"Wang Z, Zhang M, Zhang R, Liu L, Shen Y, Wang J, Lu H. Diversity of HIV-1 genotypes and high prevalence of pretreatment drug resistance in newly diagnosed HIV-infected patients in Shanghai, China. BMC Infect Dis. 2019;19:313. https:\/\/doi.org\/10.1186\/s12879-019-3927-1.","journal-title":"BMC Infect Dis"},{"key":"540_CR24","doi-asserted-by":"publisher","first-page":"797771","DOI":"10.3389\/fmicb.2021.797771","volume":"12","author":"B Zhao","year":"2021","unstructured":"Zhao B, Song W, Kang M, Dong X, Li X, Wang L, et al. Molecular network analysis reveals transmission of HIV-1 drug-resistant strains among newly diagnosed HIV-1 infections in a moderately HIV Endemic City in China. Front Microbiol. 2021;12:797771. https:\/\/doi.org\/10.3389\/fmicb.2021.797771.","journal-title":"Front Microbiol"},{"key":"540_CR25","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1017\/S0950268818000389","volume":"146","author":"M Chen","year":"2018","unstructured":"Chen M, Jia MH, Ma YL, Luo HB, Chen HC, Yang CJ, et al. The changing HIV-1 genetic characteristics and transmitted drug resistance among recently infected population in Yunnan, China. Epidemiol Infect. 2018;146:775\u201381. https:\/\/doi.org\/10.1017\/S0950268818000389.","journal-title":"Epidemiol Infect"},{"key":"540_CR26","doi-asserted-by":"publisher","first-page":"731280","DOI":"10.3389\/fpubh.2021.731280","volume":"9","author":"D Yuan","year":"2021","unstructured":"Yuan D, Yu B, Li Y, Wang Z, Liu M, Ye L, et al. Prevalence and molecular epidemiology of transmitted drug resistance and genetic transmission networks among newly diagnosed people living with HIV\/AIDS in a minority area, China. Front Public Health. 2021;9:731280. https:\/\/doi.org\/10.3389\/fpubh.2021.731280.","journal-title":"Front Public Health"},{"key":"540_CR27","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1093\/jac\/dkz134","volume":"74","author":"GA Yendewa","year":"2019","unstructured":"Yendewa GA, Sahr F, Lakoh S, Ruiz M, Pati\u00f1o L, Tabernilla A, et al. Prevalence of drug resistance mutations among ART-failure and -experienced HIV-infected patients in Sierra Leone. J Antimicrob Chemother. 2019;74:2024\u20139. https:\/\/doi.org\/10.1093\/jac\/dkz134.","journal-title":"J Antimicrob Chemother"},{"key":"540_CR28","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1093\/infdis\/jiaa413","volume":"223","author":"SN Rich","year":"2021","unstructured":"Rich SN, Poschman K, Hu H, Mavian C, Cook RL, Salemi M, et al. Sociodemographic, ecological, and spatiotemporal factors associated with human immunodeficiency virus drug resistance in Florida: a retrospective analysis. J Infect Dis. 2021;223:866\u201375. https:\/\/doi.org\/10.1093\/infdis\/jiaa413.","journal-title":"J Infect Dis"},{"key":"540_CR29","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1007\/s00705-018-3825-7","volume":"163","author":"Z Shu","year":"2018","unstructured":"Shu Z, Chen Y, Abudureyimu A, Li T, Yuan T, Ma J, et al. Surveillance of HIV-1 drug resistance in Xinjiang: high prevalence of K103N in treatment-na\u00efve individuals. Arch Virol. 2018;163:2111\u20139. https:\/\/doi.org\/10.1007\/s00705-018-3825-7.","journal-title":"Arch Virol"},{"key":"540_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens11080866","author":"S Zheng","year":"2022","unstructured":"Zheng S, Wu J, Hao J, Wang D, Hu Z, Liu L, et al. Epidemic characteristics of HIV drug resistance in Hefei, Anhui Province. Pathogens. 2022. https:\/\/doi.org\/10.3390\/pathogens11080866.","journal-title":"Pathogens"},{"key":"540_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1620\/tjem.247.1","volume":"247","author":"K Dong","year":"2019","unstructured":"Dong K, Ye L, Leng Y, Liang S, Feng L, Yang H, et al. Prevalence of HIV-1 drug resistance among patients with antiretroviral therapy failure in Sichuan, China, 2010\u20132016. Tohoku J Exp Med. 2019;247:1\u201312. https:\/\/doi.org\/10.1620\/tjem.247.1.","journal-title":"Tohoku J Exp Med"},{"key":"540_CR32","doi-asserted-by":"publisher","first-page":"e0150722","DOI":"10.1128\/spectrum.01507-22","volume":"10","author":"M Mori","year":"2022","unstructured":"Mori M, Ode H, Kubota M, Nakata Y, Kasahara T, Shigemi U, et al. Nanopore sequencing for characterization of HIV-1 recombinant forms. Microbiol Spectr. 2022;10:e0150722. https:\/\/doi.org\/10.1128\/spectrum.01507-22.","journal-title":"Microbiol Spectr"},{"key":"540_CR33","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1089\/AID.2019.0042","volume":"35","author":"A Acharya","year":"2019","unstructured":"Acharya A, Fonsah JY, Mbanya D, Njamnshi AK, Kanmogne GD. Near-full-length genetic characterization of a novel HIV-1 unique recombinant with similarities to A1, CRF01_AE, and CRFO2_AG viruses in Yaound\u00e9, Cameroon. AIDS Res Hum Retroviruses. 2019;35:762\u20138. https:\/\/doi.org\/10.1089\/AID.2019.0042.","journal-title":"AIDS Res Hum Retroviruses"},{"key":"540_CR34","doi-asserted-by":"publisher","first-page":"4122","DOI":"10.1038\/s41598-021-82872-3","volume":"11","author":"S Ryou","year":"2021","unstructured":"Ryou S, Yoo M, Kim K, Kim S, Kim SI, Kim YJ, et al. Characterization of HIV-1 recombinant and subtype B near full-length genome among men who have sex with men in South Korea. Sci Rep. 2021;11:4122. https:\/\/doi.org\/10.1038\/s41598-021-82872-3.","journal-title":"Sci Rep"},{"key":"540_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/v12010063","author":"MM Lunar","year":"2020","unstructured":"Lunar MM, Mlakar J, Zorec TM, Poljak M. HIV-1 unique recombinant forms identified in Slovenia and their characterization by near full-length genome sequencing. Viruses. 2020. https:\/\/doi.org\/10.3390\/v12010063.","journal-title":"Viruses"}],"container-title":["AIDS Research and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-023-00540-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12981-023-00540-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-023-00540-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,28]],"date-time":"2023-06-28T04:06:00Z","timestamp":1687925160000},"score":1,"resource":{"primary":{"URL":"https:\/\/aidsrestherapy.biomedcentral.com\/articles\/10.1186\/s12981-023-00540-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,28]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["540"],"URL":"https:\/\/doi.org\/10.1186\/s12981-023-00540-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2150905\/v1","asserted-by":"object"}]},"ISSN":["1742-6405"],"issn-type":[{"value":"1742-6405","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,28]]},"assertion":[{"value":"10 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Suzhou Center for Disease Control and Prevention (CDC) ethics committee approved the study and all experiments were in line with relevant rules and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"There were no competing interests of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"41"}}